Experimental Weight Loss Injection 'Retatrutide' Fuels Black Market Amidst Safety Concerns
Translated & summarized from N12 by baba
An experimental weight loss injection called Retatrutide (Rata) is being sold illegally on social media and the black market, despite not being approved for public use. While studies show promising results, doctors warn of significant risks associated with unsupervised use, including the potential for counterfeit or mislabeled products. Israelis are actively seeking Rata online, with some reporting dramatic weight loss and fewer side effects than approved drugs. Pharmaceutical company Eli Lilly plans to seek FDA approval in 2027, but currently, legal access is limited to clinical trials.
The story in 6 lines · by baba
- An experimental weight loss drug, Retatrutide (Rata), is being sold illegally online despite lacking regulatory approval.
- Social media platforms are flooded with testimonials and illicit deals for Rata, fueling a black market.
- Doctors warn of serious dangers from unsupervised use and the risk of counterfeit or mislabeled products.
- Retatrutide targets three hormone receptors, showing up to 30% weight loss in clinical studies.
- Eli Lilly plans to seek FDA approval for Retatrutide, with potential approval expected around 2027.
- Legal access to Retatrutide in Israel is currently restricted to approved clinical trials.
A new experimental weight loss injection, Retatrutide, or 'Rata,' is generating significant buzz and controversy, despite not yet being approved for public use. While still in clinical trials, social media platforms are flooded with reports of dramatic weight loss, recommendations, and illicit deals for the drug on the black market. Doctors are warning of the dangers of unsupervised use, but this has not deterred individuals seeking rapid weight loss.
Retatrutide works by targeting three hormone receptors (GLP-1, GIP, and glucagon), unlike previous drugs like Wegovy (one receptor) and Mounjaro (two receptors). This multi-receptor action has shown impressive weight loss of up to 30% in studies, though direct comparisons and long-term safety data are still pending. Nevertheless, online platforms are rife with testimonials of users shedding significant weight, with some even claiming it has resolved long-standing issues with hunger and health problems.
Despite the lack of regulatory approval, Israelis are actively seeking and using Rata. One 35-year-old man reported losing 35 kilograms in six months after purchasing the drug via Telegram. He stated that Rata was the only treatment that curbed his intense hunger, unlike previously approved injections which he avoided due to reported side effects like nausea and vomiting. He claims to have experienced only mild heartburn and fatigue.
However, medical professionals caution that individual experiences do not negate the drug's potential risks. The Australian Therapeutic Goods Administration (TGA) issued a warning in September following a case where a patient required hospitalization for severe vomiting and esophageal tears after using a product sold as Retatrutide, which was found to contain a dangerous concentration of semaglutide instead. Experts emphasize that Rata is only legally available in Israel through approved clinical trials and that its use outside of these trials, without medical supervision, poses significant risks due to unknown product origins, concentrations, and manufacturing conditions.
Eli Lilly, the pharmaceutical company behind Retatrutide, is reportedly planning to submit an application for FDA approval in the first quarter of 2027. Until then, medical experts stress that any use should be strictly within the confines of approved clinical research and under regular medical supervision. The allure of rapid weight loss is driving a dangerous black market for unapproved substances, with users often unaware of what they are injecting into their bodies.